Immunovaccine and IncyteAlign to Treat Patients with Platinum-Sensitive Ovarian Cancer
HALIFAX, NS: Immunovaccine, a clinical stage vaccine and immunotherapy companyhas aligned with Incyte – a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology,to evaluate the combination of Immunovaccine's novel T cell activating immunotherapy, DPX-Survivac, with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat.
Immunovaccine and Incyteare planning to evaluate the safety, tolerability and efficacy of the novel combination in platinum-sensitive ovarian cancer patients who are at high risk of recurrence. The investigational new drug (IND) application for the study, which will test the triple combination of DPX-Survivac, epacadostat and low dose oral cyclophosphamide, is expected to be filed this year in the U.S. and Canada and the study is expected to enroll approximately 20 patients.
DPX-Survivac and epacadostat both target pathways that have been linked to cancer progression, namely survivin and IDO1. DPX-Survivac is designed to activate T cells of the immune system to recognize survivin-expressing cancer cells. Epacadostat, on the other hand, is designed to inhibit IDO1-mediated immune suppression in the tumor microenvironment. It is therefore hypothesized that co-administration of these immunotherapies may lead to enhanced anti-tumor effects by both activating the immune system to recognize the cancer and simultaneously weakening its defenses.
"DPX-Survivac and epacadostat represent two exciting classes of immune based therapies with promising activity demonstrated in clinical trials."We believe a multi-pronged immune-based treatment approach may be favorable as an alternative to chemotherapy for recurrent ovarian cancer disease," says Marc Mansour, PhD, Chief Executive Officer,Immunovaccine.
By Tom Farrah, CIO & SVP, Dr Pepper Snapple Group
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Phil Jordan, CIO, Telefonica
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Dennis Hodges, CIO, Inteva Products
By Bill Krivoshik, SVP & CIO, Time Warner Inc.
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sven Gerjets, SVP-IT, DIRECTV
By Marie Blake, EVP & CCO, BankUnited
By Lowell Gilvin, Chief Process Officer, Jabil
By Walter Carvalho, VP & Corporate CIO, Carnival Corporation
By Mary Alice Annecharico, SVP & CIO, Henry Ford Health System
By Bernd Schlotter, President of Services, Unify
By Bob Fecteau, CIO, SAIC
By Jason Alan Snyder, CTO, Momentum Worldwide
By Jim Whitehurst, CEO, Red Hat
By Marc Jones, Distinguished Engineer, IBM Cloud Infrastructure